Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II, Open-Label Study of the Safety and Pharmacology of Atezolizumab Administered With or Without Bacille Calmette-Guérin in Patients With High-Risk Non-Muscle-Invasive Bladder Cancer

NCT02792192 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT02792192
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02792192 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II, Open-Label Study of the Safety and Pharmacology of Atezolizumab Administered With or Without Bacille Calmette-Guérin in Patients With High-Risk Non-Muscle-Invasive Bladder Cancer
Lead sponsor
Hoffmann-La Roche
Phase
Phase 1/2
Overall status
Terminated
Start date
June 13, 2016
Completion date
September 29, 2020
Enrollment
24 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer